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Purpose: We conducted a double-blind trial to determine whether a single intramuscular injection of
fosphenytoin prevents seizures and neurologic sequelae in children with acute coma.
Methods: We conducted this study at Kiliﬁ District Hospital in coastal Kenya and Kondele Children's Hospital
in western Kenya. We recruited children (age, 9 months to 13 years) with acute nontraumatic coma. We
administered fosphenytoin (20 phenytoin equivalents/kg) or placebo and examined the prevalence and
frequency of clinical seizures and occurrence of neurocognitive sequelae.
Results: We recruited 173 children (median age, 2.6 [interquartile range, 1.7-3.7] years) into the study; 110
had cerebral malaria, 8 had bacterial meningitis, and 55 had encephalopathies of unknown etiology. Eighty-
ﬁve children received fosphenytoin and 88 received placebo. Thirty-three (38%) children who received
fosphenytoin had at least 1 seizure compared with 32 (36%) who received placebo (P= .733). Eighteen (21%)
and 15 (17%) children died in the fosphenytoin and placebo arms, respectively (P= .489). At 3 months after
discharge, 6 (10%) children in the fosphenytoin arm had neurologic sequelae compared with 6 (10%) in the
placebo arm (P = .952).
Conclusion: A single intramuscular injection of fosphenytoin (20 phenytoin equivalents/kg) does not prevent
seizures or neurologic deﬁcits in childhood acute nontraumatic coma.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license., Coast, Kenya, and Kondele
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Acute coma in children is associated with high mortality and
signiﬁcant neurocognitive sequelae among survivors[1,2]. In sub-
Saharan Africa, the most common causes of acute nontraumatic coma
are cerebral malaria (CM), acute bacterial meningitis (ABM), and viral
encephalitides [3,4]. Seizures are common in these encephalopathies,
and prolonged and multiple seizures are associated with death and
neurologic sequelae [5,6]. Such poor outcomes associated with
seizures could be caused by neuronal damage by excitotoxins released
by repeated neuronal ﬁring, inadequate cerebral blood ﬂow for
metabolic demand in the context of impaired cerebral-vascularlicense.
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and aspiration of gastric contents during seizures [7,8]. Alternatively,
seizures may be a marker of neurologic damage rather than the cause.
If seizures do cause neuronal damage, prevention of their occurrence
may reduce mortality and neurocognitive sequelae.
In CM, up to 80% of children present with a history of seizures
and 60% have seizures during admission [5]. A placebo-controlled
trial of a single intramuscular (IM) injection of phenobarbital (20
mg/kg) as a prophylactic antiepileptic drug (AED) in children with
CM showed more than 50% reduction in the incidence of seizures
in those who received phenobarbital, with weak evidence for
decrease in neurologic sequelae [9]. However, the mortality was
more than double in those given phenobarbital due to respiratory
depression in these unventilated children. Fosphenytoin is an
effective AED, causes minimal cardiorespiratory depression, and
being water soluble, can be given intramuscularly, a useful
characteristic in resource-poor regions. It has been used for the
prevention of seizures in patients with traumatic brain injury (TBI)
and in other neurosurgery patients [10]. In a preliminary
pharmacokinetic study among children with severe falciparum
malaria, IM fosphenytoin (18 phenytoin equivalents (PE)/kg)
rapidly (5-20 minutes) achieved unbound plasma phenytoin
concentrations within the therapeutic range and controlled status
epilepticus in 64% of patients [11]. In a second study in a similar
group of children, a single dose of I.M. fosphenytoin (18 PE/kg)
rapidly achieved and sustained plasma total phenytoin concentra-
tions of more than 10 μg/mL for more than 72 hours and unbound
concentrations of more than 1 μg/mL, appropriately within
therapeutic range, for 24 hours [12]. Only 30% of the children
had clinical seizures compared with the expected 60%, and no
signiﬁcant cardiorespiratory depression was observed. On the basis
of these ﬁndings, we investigated whether a single IM injection of
fosphenytoin would provide seizure prophylaxis for at least an
initial 24 hours of admission, the crucial time when most children
with acute encephalopathies die in this setting, and when timely
appropriate management in a basic health facility may be lifesaving
before referral to a higher-level facility if necessary. Pharmacoki-
netic modeling indicated that IM fosphenytoin at a dose of 20 PE/
kg would provide appropriate prolonged therapeutic concentrations
without any adverse effects.
2. Materials and methods
The main null hypothesis for this study was that a single IM
injection of fosphenytoin (20 PE/kg) did not reduce the frequency
or prevalence of seizures in children with acute nontraumatic coma.
We used a randomized double-blind placebo-controlled trial study
design (ISRCTN11862726) (http://www.controlled-trials.com/
ISRCTN11862726). The study was approved by the Kenya Medical
Research Institute Ethics Review Committee and was conducted in
accordance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments. All patients
recruited into the study provided written informed consent.
2.1. Setting
We conducted this study at the high-dependency units (HDU)
of Kiliﬁ District Hospital (KDH) and Kondele Children's Hospital
(KCH). Kiliﬁ District Hospital is situated in the rural coast of Kenya
in an area of stable malaria transmission. It has a 35-bed pediatric
unit that admits more than 5000 children annually and is
supported by a 7-bed HDU. Kondele Children's Hospital is a
tertiary referral hospital located in Kisumu District, a region with
stable malaria transmission. Kondele Children's Hospital has a 62-
bed pediatric ward with a 7-bed HDU and admits approximately
6000 children annually.2.2. Study population
We recruited children aged between 9 months and 13 years who
were not able to localize a painful stimulus (Blantyre Coma Score ≤2),
30 minutes after treatment of a seizure or correction of hypoglycemia
(blood glucose b2.5mmol/L). The Blantyre Coma Score is a simple score
of coma status, based on assessment of motor, verbal response, and eye
opening, and preferred in malaria endemic areas because it is more
speciﬁc and has better interobserver agreement among health workers
in this setting compared with the other coma scales [13]. We did not
consider children younger than 9 months because at that developmen-
tal age, they cannot localize painful stimuli, a key criterion in our
assessment of coma. We excluded children with a history of epilepsy,
signiﬁcant developmental delay, TBI, or sickle cell disease or those who
had received phenytoin for treatment of seizures before presentation.
2.3. Study duration
We started enrollment of patients in December 2004 at KDH and in
March 2008 at KCH after an application to add a second site in
consideration of the low recruitment rate at the initial site. The study
was interrupted twice, in April 2006 and July 2008, because of
difﬁculty in obtaining stock of study drug. The study was terminated
on March 31, 2009, as guided by a Data Safety and Monitoring Board
(DSMB) interim analysis indicating futility in continued recruitment
and in consideration of the continued slow recruitment rate.
2.4. Standard care
On admission, patients underwent initial resuscitation according
to standard guidelines [14,15]. All children were initially treated with
parenteral ﬁrst-line antimicrobials and antimalarials until otherwise
guided by the results of the initial 3 malaria blood slides taken 8 hours
apart, blood, urine or cerebrospinal ﬂuid (CSF) culture, and CSF
microscopy and biochemistry results. Aciclovir was not available.
Children who presented with seizures lasting at least 5 minutes even
after correction of hypoglycemia received intravenous diazepam (0.3
mg/kg) or IM paraldehyde (0.4 mL/kg). Second-line agents were
intravenous phenobarbital (15 mg/kg initial dose and 2.5-5 mg kg−1
d−1 maintenance dose for at least 3 days) and sodium valproate (25
mg/kg). Intravenous thiopental (0.4 mg/kg) or midazolam (initial
dose 0.3 mg/kg and maintenance 0.1 mg kg−1 h−1) was given if the
seizures were refractory to second-line drugs. A lumbar puncture was
done when the patient was stable, and the CSF was examined for
evidence of infection. Mechanical ventilatory support was not
available other than bag and mask ventilation during resuscitation.
2.5. Study procedures
After initial resuscitation, the study compound (fosphenytoin or
0.9% saline) was administered intramuscularly on the upper lateral
aspect of the right thigh. The site of injectionwasmarked using a black
marker pen to observe for local reactions. Thenceforth, vital signs
weremeasured and documented every 10 to 20minutes for the next 4
hours, after which the rate ofmonitoring was reduced to 2 hourly for 4
hours and then 4 hourly until discharge from the HDU. Monitoring
was undertaken until the child regained consciousness. The following
information was documented on the case report form during
monitoring: episodes of clinical seizure episodes and abnormal
motor posturing, anticonvulsant drug administration, clinical details
of cardiorespiratory status, and any other signiﬁcant clinical events.
Adverse events (AEs) were observed for and serious AEs (SAEs) were
reported to the DSMB and the Ethics Review Committee within 24
hours of occurrence.
Plasma samples collected at the time of clinical and laboratory
review 4 hours after administration of the study drug and CSF samples
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concentrations. The assay method has been described previously with
0.5 μg/mL as the lowest limit of detection [11].
Continuous electroencephalographic (EEG) monitoring was per-
formed on alternate study subjects over the initial 72 hours of
observation or until the child regained consciousness, whichever was
earlier. An event was considered serious if it resulted in death, was life
threatening, caused persistent or signiﬁcant disability, or resulted in
the prolongation of hospitalization. At discharge, neurologic deﬁcits
were examined for and cognitive assessment using event-related
potentials (ERPs) was undertaken, as we have previously described
[16]. Clinical review and ERP assessment were repeated at 3 months
after discharge.
2.6. Treatment allocation and blinding
Randomization was computer generated in blocks of 50 and the
drug ampoules containing either fosphenytoin (250 PE at 50 PE/mL)
or placebo (5 mL of 0.9% saline) were numbered from 1 to 500 based
on this randomization. The recruiting study investigators were blind
to the treatment allocation. The list linking the study number to the
intervention arm was retained by the DSMB. To ensure double
blinding, the interventions, both colorless liquids, were presented in
identical ampoules and were both administered at 0.4 mL/kg.
Neurocognitive assessment at discharge and at 3-month review
were conducted by study investigators (S.G., R.I., E.C., A.M., and M.K.)
who were all blind to the study drug allocation.
2.7. Analysis
Sample size determination of 250 in each study arm was based on
a desired ability to be able to detect a 50% reduction (from 27% of
prolonged seizures observed in a previous study to 13.5%) in patients
with at least 1 seizure, lasting longer than 5 minutes, allowing for a
20% loss to follow-up and 90% power at the conventional 5%
signiﬁcance level [5]. We recorded the study data on paper-based
case report forms, which were then double entered onto a Visual
Foxpro (Visual FoxproDevelopingCentre,Microsoft,Wash) (version9, x)Fig. 1. Study ﬂowchart. Children who were recruited against pdatabase. We analyzed the data using STATA (version 11.0; StataCorp
LP, College Station., Tex). We veriﬁed that there were no signiﬁcant
differences in the baseline clinical and laboratory parameters between
the 2 study sites before pooling the data. We analyzed the data as
intention to treat. The primary outcome variables were the number and
prevalence of clinical seizures lasting at least 5 minutes and the
prevalence of neurocognitive sequelae at 3-month review post-
discharge. The secondary outcome variables were the prevalence of
seizures of any duration, the prevalence of seizures detected by EEG
monitoring, the prevalence of abnormal motor posturing, the preva-
lence of neurocognitive deﬁcits at discharge, in-hospital mortality, and
the frequency of hypotension and respiratory depression.Wemeasured
plasma phenytoin concentrations to explore the relationship between
phenytoin concentrations and the frequency of seizures. We examined
differences between the 2 arms using either the χ2 test or Fisher exact
test for categorical variables, and the unpaired t test or Wilcoxon rank
sum test for continuous variables, the choice of test being guided by the
distribution of the data. To determine cognitive outcomes, the latencies
and amplitudes of the ERP componentswere compared using repeated-
measures analysis of variance with age, treatment group, and diagnosis
as ﬁxed variables. The ERP data were analyzed using SPSS (PASW
version 18 [Chicago, Ill]) software. We described the association
between the study drugs and the outcomes using odds ratios and 95%
conﬁdence intervals (95% CIs).
3. Results
Over the study period, we recruited 173 children of an eligible
333 children (Fig. 1): 157 at the Kiliﬁ site and 16 at the Kisumu site.
They were of a median age of 2.6 (interquartile range [IQR], 1.8-3.6)
years, and 72 (42%) were female. One hundred ten (64%) children
had CM, 55 (32%) had encephalopathies of unknown etiology (EUA),
and 8 (5%) had ABM. Children with ABM (75%) had higher case
fatality than did those with EUA (20%) and CM (15%) (P b .001).
Children with EUA were more likely to have neurologic deﬁcits at
discharge compared with those with CM. Eighty-ﬁve (49%) children
received fosphenytoin, and 88 (51%) received placebo. Baseline
characteristics and diagnoses were similar across the 2 study armsrotocol were not followed up on discharge from hospital.
Table 1
Clinical features at admission
Fosphenytoin (n = 85) Placebo (n = 88)






















Time (h) between admission
and administration of
study drug (median)
2.2 (IQR, 1.6-3.9) 2.4 (IQR, 1.4-4.2)
Mean admission sodium
(mmol/L)
135 (95% CI, 133-136) 136 (95% CI, 134-137)
Mean admission potassium
(mmol/L)
4.2 (95% CI, 3.9-4.4) 4.0 (95% CI, 3.8-4.3)
Mean admission blood
glucose (mmol/L)
5.6 (95% CI, 4.9-6.4) 6.8 (95% CI, 5.8-7.8)
Mean admission hemoglobin
(g/dL)
7.8 (95% CI, 7.3-8.4) 8.4 (95% CI, 7.9-8.9)
Mean admission white cell
count (count/10−9 L)
16.4 (95% CI, 13.7-19.1) 16.9 (95% CI, 14.8-19.0)
Mean admission platelets
(count/10−9 L)
256 (95% CI, 206-305) 260 (95% CI, 216-304)
Diagnosis
CM 54 56
Unknown encephalopathy 27 28
Acute bacterial meningitis 4 4
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administration of study drug was also the same between the 2
groups. None of the children had respiratory depression requiring
bag and mask ventilation at the point of initial resuscitation before
administration of the study drug. Thirty-one (36%) children who
would later receive fosphenytoin had seizures during admissionTable 2
Prevalence of seizures, AED use, and abnormal motor postures after administration of stud
Fo
Prevalence of clinical seizures 3
Prevalence of clinical seizures within 24 h 2
Prevalence of clinical seizures ≥5 min during the whole duration of monitoring 1
Prevalence of clinical seizures ≥5 min within 24 h 1
Prevalence of clinical seizures ≥30 min during the whole duration of monitoring 4
Prevalence of clinical seizures ≥30 min within 24 h 2
Number of clinical seizures per patient within 24 h of monitoring, median (IQR) 0
Prevalence of seizures on EEG 6
Received AED after administration of study drug 3
Received AED within 24 h after administration of study drug 2
Received ﬁrst-line AED after study drug 2
Received ﬁrst-line AED within 24 h after study drug 2
Received second-line AED within 24 h after study drug 1
Received second-line AED after study drug 3
Prevalence of abnormal motor posturing 3




CSF phenytoin concentration (μg/mL) 2
Plasma phenytoin concentration 4 h after administration (μg/mL) 1requiring ﬁrst-line AED compared with 35 (40%) who would receive
placebo (P = .66). Six children (7%) in the fosphenytoin group went
on to require phenobarbital during this initial period before
administration of study drug compared with 8 (9%) who would
receive placebo (P = .62).
Children who received fosphenytoin had a 4-hour median plasma
phenytoin concentration of 16.8 (IQR, 13.0-19.0) μg/mL compared
with insigniﬁcant concentrations of 0.2 (IQR, 0.0-0.3) μg/mL, in those
who received placebo (P b .01). Only 2 (2%) of the children who
received fosphenytoin had 4-hour phenytoin plasma concentrations
below the therapeutic value of 10 μg/mL: 9.4 and 3.2 μg/mL. Therewas
no difference in plasma phenytoin concentrations among those who
received fosphenytoin between those who had CM (median concen-
tration, 17.19 [IQR, 13.37-18.98] μg/mL), ABM (median concentration,
17.67 [IQR, 12.44-23.92] μg/mL), and EUA (median concentration,
15.56 [IQR, 12.81-18.44] μg/mL; P = .843). Lumbar puncture was
performed at varied times after administration of the study drug
depending on the clinical progress of the patient. Children who
received fosphenytoin had a median CSF phenytoin concentration of
2.1 (IQR, 1.6-2.6) μg/mL compared with 0.1 (IQR, 0.0-0.3) μg/mL in
those who received placebo (P b .01).
3.1. Seizures, AED use, and abnormal motor posturing
Most (n= 108; 62%) of the children did not have any seizures after
administration of the study drug. Overall, there were no differences in
frequency or prevalence of clinical and EEG seizures between the 2
study arms (Table 2). Among children with CM (n = 110), there was
no difference in the prevalence of seizures between the fosphenytoin
(n = 20; 37%) and the placebo (n = 21; 38%) (P = .980) arms of the
study. The need for AED for treatment of seizures during the duration
of study monitoring was similar between the 2 study arms, except for
use of second-line AED over the whole duration of the study period,
which was signiﬁcantly lower in the placebo arm. The frequency of
seizures in children who suffered seizures was not affected by plasma
or CSF concentration of phenytoin (Supplementary Fig. 1).
3.2. Outcome
Nine children (14%; n = 65) in the fosphenytoin arm of the study
were found to havemotor deﬁcits at discharge comparedwith 14 (19%;
n = 73) in the placebo arm (P = .359; Table 3). Among children withy drug
sphenytoin (n = 85) Placebo (n = 88) Odds ratio
(95% CI)
P
3 (38%) 32 (36%) 0.90 (0.48-1.67) .733
4 (28%) 27 (31%) 1.13 (0.58-2.18) .726
7 (20%) 22 (25%) 1.33 (0.65-2.75) .432
1 (13%) 10 (11%) 1.86 (0.82-4.22) .133
(5%) 5 (6%) 1.23 (0.32-4.79) .773
(2%) 4 (5%) 2.00 (0.35-11.33) .431
(0-2); range, 0-22 0 (0-2); range, 0-30 – .666
(7%; n = 21) 10 (4%; n = 25) – .418
6 (43%) 35 (41%) 1.12 (0.60-2.06) .725
8 (34%) 32 (36%) 0.86 (0.46-1.62) .638
4 (28%) 26 (30%) 1.07 (0.55-2.06) .850
0 (24%) 23 (26%) 0.87 (0.43-1.74) .693
9 (22%) 16 (18%) 1.30 (0.61-2.74) .496
0 (35%) 18 (20%) 2.12 (1.06-4.25) .029
9 (46%) 32 (36%) 1.50 (0.81-2.78) .199
0 13 1.78 (0.81-3.90) .142
1 13 1.90 (0.87-4.14) .100
4 1.31 (0.34-5.10) .691
.1 (IQR, 1.6-2.6) 0.1 (IQR, 0.0-0.3) b .001
6.8 (IQR, 13.0-19.0) 0.2 (IQR, 0.0-0.3) b .001
Table 3
Outcome at discharge and at 3 months after admission
Fosphenytoin (n = 85) Placebo (n = 88) P
Outcome at discharge
Died 18 (21%) 15 (17%) .489
Sequelae 9 (13%; n = 67) 14 (19%; n = 73) .359a
Time to localize pain (h)b 18 (8-28) 14 (6-33) .378a
Time to regain full
consciousness (h)b
21.5 (15.5-32.5) 24 (10-48) .875




7 (12%) 11 (18%) .415
Neurologic deﬁcits 6 (10%) 6 (10%) .952
Differences in proportions examined using the χ2 test.
a Kruskal-Wallis equality of population test.
b Time to localize painful stimulus and time to regain full consciousness considered
only for those who survived without motor neurologic deﬁcits and presented as
median (IQR).
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at discharge compared with 9 (19%) in the placebo arm (P = .283).
Therewere no differences between the 2 arms of the study inmortality,Fig. 2. Event-related potential proﬁles between the 2 study groups. A, Mean P1 latencies of
treatment groups. D, Mean P2 amplitudes of treatment groups. There were observed decrea
who received placebo had signiﬁcantly shorter P1 latency compared with those who recei
between the 2 trial groups. Supplementary Fig. 1: Plasma and CSF phenytoin concentration
Plasma phenytoin concentration vs seizure count during the whole duration of in-hospital m
after administration of the study drug. C, CSF phenytoin concentration vs seizure count du
seizure count during the whole duration of in-hospital monitoring. Most of the children d
included in these plots. Children who had more than 20 seizures within the ﬁrst 24 hours (n
plot to facilitate easy interpretation of the graphs.time to localize painful stimulus, and time to regain full consciousness.
At 3 months after discharge, 7 children in the fosphenytoin arm and 11
children in the placebo arm were not followed up, having been lost to
follow-up, withdrawn, or earlier recruited against protocol (Fig. 1). At
this assessment, 10 children who had motor deﬁcits at discharge were
found to be normal. Two children, 1 in each study arm, had developed
seizures after discharge. Thus, 6 (10%) children in the fosphenytoin arm
had neurologic sequelae at 3 months compared with 6 (10%) in the
placebo arm (P= .952).
3.3. Event-related potentials
Ninety-ﬁve children (68% of those who survived by hospital
discharge) had ERP measurements recorded at 3 months after
discharge; 45 had received fosphenytoin and 50 had received placebo.
Therewas no signiﬁcant difference in age and diagnosis between the 2
treatment groups. Children with CM had signiﬁcantly longer ERP
latencies (both P1 and P2) and larger amplitudes compared with
those with unknown encephalopathies. The P1 and P2 latencies
decreased with age. Correcting for age and diagnosis, children who
received placebo had signiﬁcantly shorter P1 latency compared withtreatment groups. B, Mean P1 amplitudes of treatment groups. C, Mean P2 latencies of
sing P1 and P2 latencies with increasing age. Correcting for age and diagnosis, children
ved fosphenytoin. There was no difference in P2 latency and in P1 and P2 amplitudes
vs seizure count in children who had seizures after administration of the study drug. A,
onitoring. B, Plasma phenytoin concentration vs seizure count within the ﬁrst 24 hours
ring the whole duration of in-hospital monitoring. D, CSF phenytoin concentration vs
id not have any seizures after administration of the study drug and are therefore not
= 2) and during the whole duration of monitoring (n = 6) are also not included in the
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difference in P2 latency and in P1 and P2 amplitudes between the 2
trial groups.
3.4. Serious AEs
Ten (12%) children in the fosphenytoin group had respiratory
depression compared with 13 (15%) children in the placebo arm (P=
.560). Twenty-nine children had hypotension during the study
monitoring, 15 in the fosphenytoin group and 14 in the placebo
group (P= .760). Only 2 children were observed to have bradycardia;
both were in the placebo arm of the study. Two children in the
fosphenytoin arm had local reactions at the site of injection: 1 a
swelling and the second, induration.
4. Discussion
In this study, we investigated the efﬁcacy of a single IM injection of
fosphenytoin for preventing seizures in children with acute nontrau-
matic coma and in improving outcome. We observed no difference
between the 2 arms in the prevalence and frequency of seizures.
Occurrence of neurocognitive sequelae and mortality were similar
between the 2 groups. Event-related potentials at 3 months review
after discharge were similar between the 2 groups, except for P1
latency, which was shorter in children who received placebo,
suggesting better cognitive outcome in this group [17,18].
This was a randomized double-blind trial, with the investigators
blinded to the treatment allocation until after the analysis. The
baseline clinical characteristics between the 2 groups were similar.
The median time to peak unbound plasma phenytoin concentration in
a similar group of children receiving antibiotics has previously been
shown to be 4 hours [12]. Except for 2 children, those who received
fosphenytoin achieved optimal phenytoin concentration as indicated
by blood samples taken 4 hours after administration of the study drug.
A previous pharmacokinetic study indicated that a single IM injection
of a slightly lower dose of fosphenytoin quickly achieved optimal
levels and sustained plasma concentrations of unbound phenytoin
within therapeutic range for at least 24 hours [12]. Albumin and
protein levels were not consistently determined in our patients, but
low levels would have increased the free levels of phenytoin further. It
would have been useful to correct measured phenytoin levels for the
determined protein levels and relate this to seizure prevention.
Lumbar puncture was done at varied times after administration of the
study drug, depending on the clinical course. In patients who died
shortly after admission or who remained critically ill for a prolonged
period during their acute illness, an opportunity for a lumbar puncture
did not present. Thus, it was difﬁcult to discern the relationship
between seizure prevention and the plasma/CSF phenytoin ratio. In
our study, an interim analysis suggested futility in continuation of the
trial. That there is no clear beneﬁt in the prophylactic use of
fosphenytoin over placebo in preventing seizures or improving
outcome in our group of children with nontraumatic coma, including
CM speciﬁcally, is an unexpected ﬁnding.
The design of our trial allowed for initial resuscitation and
treatment of any seizures observed at admission before recruitment.
Thirty-eight percent of the children recruited into the study received
at least 1 AED during resuscitation before administration of the study
drug. Lack of initial seizure control in acute encephalopathies begets
more seizures, and conversely, appropriate initial seizure treatment
preventsmore seizures. Thus, efﬁcient seizure treatment during initial
emergency resuscitation could have diminished the apparent effect of
prophylactic AED. Even so, further analysis of our data did not suggest
a difference in risk of seizures between the 2 groups even among
patients who did not receive AED treatment during resuscitation
at admission.The need for second-line AED after administration of the study
drug was greater in the fosphenytoin group compared with the
placebo group. However, narrowing to the ﬁrst 24 hours of
monitoring during which period therapeutic levels of unbound
phenytoin are likely to be sustained, this difference is not apparent.
It is possible that this difference in need for AED, apparent after lapse
of a period when the therapeutic window is likely to have occurred,
may be caused by rebound seizures caused by a rapid drop in
phenytoin levels not sustained further by maintenance dosages, a
phenomenon well described in epilepsy in relation to acute AED
withdrawal [19].
The role of fosphenytoin in seizure prophylaxis among patients
with TBI and neurosurgery patients is well established in developed
country settings [10]. Admittedly, such use entails repeat mainte-
nance dosages, a practice that we would likely uphold with continued
management beyond the initial 24 hours of resuscitation and acute
management. It is possible that a higher dose of fosphenytoin may be
more effective in reducing seizures and improving outcome, but
patients may need more intensive care support than is available in
most health facilities in sub-Saharan Africa. There is a clearer
understanding of the pathophysiology of TBI, and perhaps, the ability
to determine the time of neurologic insult provides a beneﬁcial
intervention during an appropriate window of opportunity. Among
patients with nontraumatic encephalopathy, it is difﬁcult to deter-
mine the time of onset of neurologic insult. Seizures may be a
consequence rather than cause of already existent neurologic damage
and, perhaps, less amenable to prevention. Prolonged seizures
associated with fever have been shown to be less responsive to
phenytoin and other AED treatment [20]. Sodium channel mutations
are associated with prolonged seizures in the context of fever, altering
mechanisms of stopping seizures and the afﬁnity of sodium-channel
blockers such as phenytoin [21]. Thus, it may be that strategies to
prevent seizures may require greater insight into pathophysiological
processes of nontraumatic encephalopathies. It will be useful to
investigate other newer AEDs like levetiracetam, which is more
efﬁcacious for prevention of seizures among neurosurgical patients
when compared with phenytoin and yet has minimal adverse effects
[22]. The overall incidence of seizures lasting at least 5 minutes within
the ﬁrst 24 hours after administration of study drug was 12%. This is a
lower incidence than the 27% anticipated during the design of the
study. However, this observation was in a setting where seizure
management during initial resuscitation was optimal, thus limiting
seizure recurrence during the subsequent inpatient stay. The need for
readjustment of effect parameters in calculating sample sizes for
similar future trials may therefore need to be considered.
From the results of our study, there appears to be no beneﬁt in
using IM fosphenytoin at 20 PE/kg for seizure prophylaxis in children
with acute nontraumatic coma.
Supplementarymaterials related to this article can be found online
at http://dx.doi.org/10.1016/j.jcrc.2013.09.001.
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